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among each other and with AHI and Epworth scores. SF-6D 
utility after 4 months of CPAP had changed by 0.04 (0.02; 
0.12, p = 0.026).  Conclusions: Utility indices measured by dif-
ferent instruments vary largely and some indices reflect the 
impaired quality of life in OSA poorly. Interpretation of cost-
effectiveness analyses should account for the utility instru-
ment used. 
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 Introduction 
 The effectiveness of novel medical treatments is tradi-
tionally evaluated in terms of the objective effects on 
morbidity and mortality. In recent times, increasing em-
phasis has been placed on subjective outcomes such as 
quality of life assessed by generic and disease-specific 
questionnaires that provide profiles of subjective health 
perception in different domains  [1–3] . For cost-effective-
ness analysis, quality of life is expressed by a single index 
measure intended to convey the utility that a person de-
rives from his or her health state  [4] . The utility index is 
defined as the subjective preference of a patient for a giv-
en health state and rated on a scale anchored at 0 (corre-
sponding to death) and 1 (corresponding to perfect 
health)  [5, 6] . By multiplying the utility index by the years 
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 Abstract 
 Background: Utility indices are used in cost-effectiveness 
analyses as a measure of quality of life reflecting the patient’s 
preference for a given health state on a scale anchored at 0 
(corresponding to death) to 1 (perfect health). It is uncertain 
which utility instruments are most suitable for application in 
patients with the obstructive sleep apnea syndrome (OSA). 
 Objectives: To compare utility indices obtained in OSA pa-
tients by various instruments.  Methods: In 66 untreated OSA 
patients (median Epworth score 12, apnea/hypopnea index, 
AHI, 57/h), five different utility instruments were employed. 
In 34 OSA patients, changes in utility after 4 months of con-
tinuous positive airway pressure (CPAP) were retrieved from 
published SF-36 data.  Results: In 66 OSA patients, median 
(quartiles) utility indices were: standard gamble 0.97 (0.89; 
0.99); time trade-off 0.94 (0.81; 0.99); EuroQol questionnaire 
(EQ-5D) 0.92 (0.83; 1.00); Euro-thermometer visual analog 
scale 0.80 (0.70; 0.90); SF-36 questionnaire (SF-6D) 0.75 (0.69; 
0.85; p  ! 0.05 SF-6D and Euro-thermometer utility vs. other 
indices). Different utility indices were poorly correlated 
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spent in a particular health state, quality-adjusted life 
years are computed. The ratio of increased costs divided 
by the quality-adjusted life years gained by a medical in-
tervention represents the cost-effectiveness ratio  [4] . De-
cisions on allocation of financial resources for health care 
are increasingly guided by cost-effectiveness analyses. 
Since the utility index is a main component of such anal-
yses, its reliable measurement is essential. Various instru-
ments have been used to obtain utility indices  directly (i.e. 
the standard gamble and time trade-off methods  [5] and 
the ‘Euro-thermometer’ visual analog scale  [7] ), and  in-
directly from questionnaires such as the medical outcome 
health survey SF-36  [8] or the EuroQol questionnaire  [7] , 
which provide the SF-6D and the EQ-5D utility indices, 
respectively. The performance of different utility instru-
ments in various settings is not well established. Utility 
indices may be affected by age, gender, socioeconomic 
status and cultural factors in addition to the individual 
health preference of a patient with a particular disease  [9, 
10] . Therefore, utility instruments have to be validated in 
the specific setting where they are intended to be ap-
plied.
 The obstructive sleep apnea syndrome (OSA) is a 
common disorder affecting at least 2–4% of adults in the 
US population  [11] , and the prevalence is expected to 
increase due to the epidemic of obesity. OSA patients are 
affected by daytime sleepiness, decreased concentration 
and irritability  [12] , and the disorder is an independent 
risk factor for cardiovascular diseases  [13, 14] and sleep-
iness-related traffic and work accidents  [15] . Since OSA 
has a considerable impact on health economics  [16] , 
evaluating cost-effectiveness of various treatments such 
as nocturnal continuous positive airway pressure 
(CPAP), mandibular advancement devices and surgical 
interventions would be desirable. However, utility in-
struments have not been rigorously validated for appli-
cation in OSA patients. Thus, the objective of this study 
is to compare utility indices obtained by different in-
struments in OSA patients and to correlate utility indi-
ces with other measures of quality of life, symptoms and 
the severity of sleep-related breathing disturbances. It 
was hypothesized that the performance of various util-
ity instruments would vary. Furthermore, we evaluated 
whether one particular utility instrument, the SF-36 
questionnaire-derived SF-6D utility index, reflects 
changes in quality of life achieved by CPAP therapy in 
OSA patients. For this purpose, we derived SF-6D util-
ity indices from data collected in a previously published 
study in OSA patients at baseline and after 4 months of 
CPAP therapy  [17] .
 Patients and Methods 
 Patients  
 Successive patients with OSA referred to the Pulmonary Divi-
sion of the Sleep Disorder Center, University Hospital of Zurich, 
were asked to participate in the study. OSA was diagnosed based 
on typical symptoms such as habitual snoring, excessive daytime 
sleepiness, an Epworth sleepiness scale score  6 8  [18] and an ap-
nea/hypopnea index (AHI)  1 10/h during a cardiorespiratory 
sleep study. Patients with comorbidities that were thought to sig-
nificantly affect their quality of life (in particular psychiatric, in-
ternal medical and neurologic disorders) were excluded. Informed 
consent was obtained and the protocol was approved by the hos-
pital ethics committee.
 Utility indices were additionally derived from SF-36 question-
naires obtained in 33 OSA patients (median age: 50 years; quar-
tiles: 45 and 58 years) in a previous study  [17] . These data includ-
ed evaluations within 1 month before and 4 months after initia-
tion of CPAP therapy.
 Utility Assessment 
 Three instruments for  direct utility assessments were em-
ployed: the standard gamble, the time trade-off and the visual 
analog scale (‘Euro-thermometer’).
 Standard Gamble . This test  [5] was performed using a custom-
made interactive computer application. Patients were asked to 
choose between two theoretical alternatives presented on the 
computer screen ( fig. 1 ): either to continue their life in the current 
health state or to accept an offered therapy. If they chose the ther-
apy, this was associated with a certain chance (probability) of at-
taining perfect health, but this was also afflicted by a certain risk 
of immediate death (risk or probability of immediate death = 1 – 
probability of perfect health). By systematically changing the 
probability of attaining perfect health and its connected risk of 
immediate death, the point of indifference was determined in an 
iterative procedure. The probability of perfect health at the point 
of indifference was taken as the utility of the individual’s current 
health state.
 Time Trade-Off . This test  [5] was also performed using a cus-
tom-made interactive computer application ( fig. 1 ). Patients were 
asked to choose between two theoretical alternatives: either live 
for 20 years in their current health state or live in perfect health 
but for a shorter time period. The number of years the patients 
were willing to trade off was varied systematically until a point of 
indifference was reached. The ratio of years at the point of indif-
ference divided by 20 (i.e. the selected time horizon) correspond-
ed to the utility index.
 Visual Analog Scale (‘Euro-Thermometer’) . The Euro-ther-
mometer  [7] is part of the EuroQol questionnaire EQ-5D. Patients 
had to mark their perceived current health state with a pencil on 
a piece of paper that contained a line with a scale from 0 (corre-
sponding to worst imaginable health or death) to 100 (corre-
sponding to best imaginable, perfect health). The value corre-
sponding to the mark on the scale divided by 100 was taken as the 
utility index ( fig. 1 ).
 In addition, two instruments for  indirect utility assessments 
were employed. Utility was derived from answers to questions on 
various domains of quality of life. The responses were weighted 
and summed to obtain the utility index according to evaluations 
obtained in reference populations as described elsewhere  [19, 20] .
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 Short-Form 6 Dimensions (SF-6D). The SF-6D is derived from 
the short form of the medical outcome questionnaire SF-36, a ge-
neric quality-of-life questionnaire  [1, 19] . Patients completed the 
SF-36 on paper. The answers from 11 of the 36 questions repre-
senting six dimensions were used to compute the utility index 
based on evaluations in a British population  [1, 19] . The scores in 
the eight domains of the SF-36, and the mental and physical com-
ponent scores were also computed.
 EuroQol-5 Dimensions (EQ-5D). The EQ-5D is a generic ques-
tionnaire for the evaluation of quality of life encompassing five 
dimensions. There is one question for each dimension which can 
be answered by three levels of impairment  [2, 20] . Patients com-
pleted the questionnaire on paper. The scores for the five domains 
were computed and the EQ-5D utility index derived according to 
evaluations in a British population  [10, 21] .
 Protocol 
 Study participants were asked to perform utility assessment 
after receiving detailed information on the various tests. An in-
vestigator coached the participants performing the computer-
based tests and questionnaires. If any participant did not under-
stand how to handle the computer programs or did not under-
stand the questions, the investigator gave additional explanations 
and, in some cases, the tests were restarted. The time to complete 
all utility assessments was assessed.
 To gather utility indices before and after 4 months of CPAP 
therapy, SF-36 questionnaires from OSA patients who had par-
ticipated in a previous study  [17] were reanalyzed and the change 
in the SF-6D utility index with introduction of treatment was 
evaluated.
 Data Analysis and Statistics 
 Results were summarized by medians (quartiles) or means 
(SD) for non-normally and normally distributed outcomes, re-
spectively. Utility values obtained in the same participant by dif-
ferent instruments were compared by identity plots, by comput-
ing Spearman correlation coefficients and by Wilcoxon matched 
pair tests. Data from different groups were compared by the 
Mann-Whitney U test. Spearman correlations were computed be-
tween utility indices and the AHI and the Epworth sleepiness 
score. A probability of p  ! 0.05 was considered statistically sig-
nificant.
your current
health
best
100
0
worst
50
c
 Fig. 1. Utility indices were obtained by the three direct instru-
ments in addition to the indirect utility indices derived from the 
SF-36 and the EuroQol questionnaires.  a In the standard gamble 
test, patients had to select among two options displayed on the 
computer screen, i.e. to accept a new therapy associated with per-
fect health but a certain risk of immediate death or to remain in 
their current health state. The utility index was determined as
[1 – (% risk of death/100)] at the point of indifference.  b In the 
time trade-off test, patients were asked whether they preferred to 
live in perfect health but trade off a few years of their life-time 
(assumed time horizon of 20 years) or to stay in their current 
health state. The number of years traded off was varied to the 
point of indifference, and the utility index was taken as the ratio 
[1 – (years traded off /20)].  c In the Euro-thermometer visual an-
alog scale, the patients positioned their current health state on a 
scale ranging from 0 (worst imaginable health or death) to 100 
(best imaginable, perfect health). The value on the scale divided 
by 100 was taken as the utility index. 
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 Results 
 Sixty-six OSA patients participated in the study ( ta-
ble 1 ). In some patients, utility indices could not be ob-
tained by some of the five methods because of technical 
failures or incomplete questionnaire data and, in 1 pa-
tient, because he did not understand the principles of the 
standard gamble test. Therefore, the number of available 
utility indices collected by the different instruments var-
ies between 56 and 66. OSA patients required a mean 
( 8 SD) time of 20  8 8 min to complete utility assess-
ments by all five instruments. Most patients required de-
tailed explanations before they were able to perform the 
standard gamble and time trade-off tests while they were 
generally able to complete the SF-36, the EQ-5D and the 
Euro-thermometer tests after brief instructions.
 Patient characteristics are summarized in  table 1 along 
with multidimensional quality of life assessed by the ge-
neric questionnaires SF-36 and EQ-5D. The OSA patients 
had moderate/severe sleep-related breathing disturbanc-
es and moderate subjective daytime sleepiness. Com-
pared to a US reference population of corresponding age 
and gender reported by Ware et al.  [1] , their SF-36 qual-
ity of life was reduced in several domains, whereas the 
medians of the EQ-5D domains had a value of 1, suggest-
ing no impairment.
 Results of utility assessments are summarized in  ta-
ble 2 .  Figure 2 shows histograms of utility indices and 
AHI in the OSA patients. The median SF-6D utility index 
in OSA patients was significantly lower than the corre-
sponding values obtained by all other instruments with 
the exception of the Euro-thermometer utility index that 
was similarly low ( table 2 ). In contrast, the standard gam-
ble and time trade-off utility indices were higher than 
those obtained by all other instruments and their value 
was close to 1, suggesting a ceiling effect in these two in-
dices ( fig. 2 ).
 In  table 3 , Spearman rank order correlations of utility 
indices obtained by the five different instruments are 
presented.
 The standard gamble and the time trade-off utility in-
dices were correlated among themselves but not with any 
of the other utility indices. The EQ-5D and the Euro-ther-
mometer VAS were correlated among themselves and 
with the SF-6D index. We further evaluated whether util-
ity indices were correlated with selected measures of qual-
ity of life that were impaired in OSA patients ( table 2 ). 
This analysis revealed that the SF-36 physical component 
summary was significantly correlated with utility indices 
from the EQ-5D, the Euro-thermometer visual analog 
scale and the SF-6D ( table 3 ). The EQ-5D pain/discomfort 
domain was significantly correlated with utility indices 
from the EQ-5D, the Euro-thermometer and the SF-6D 
Table 1. Patient characteristics and multidimensional, generic 
quality of life
Number of patients (female) 66 (8)
Age, years 55 (47; 61)
AHI, events/h 57 (38; 72)
Epworth score 12 (10; 15)
SF-36 quality of life norm
Physical function 85 (65; 90)* [90]
Role physical 75 (50; 100)* [96]
Bodily pain 100 (62;100) [78]
General health 72 (57; 82) [72]
Vitality 55 (35; 70)* [66]
Social function 100 (75; 100)* [99]
Role emotional 100 (67; 100)* [100]
Mental health 80 (64; 88) [80]
Physical component summary 49 (40; 54) [50]
Mental component summary 52 (45; 56) [50]
EQ-5D quality of life
Mobility 1 (1; 1)
Self-care 1 (1; 1)
Usual activities 1 (1; 1)
Pain/discomfort 1 (1; 2)
Anxiety/depression 1 (1; 1)
Medians (lower quartile; upper quartile). Transposed SF-36 
scores are presented with a range from 0 to 100, with higher values 
corresponding to better quality of life. EQ-5D domains are rated 
on a scale from 1 (no impairment) to 3 (maximal impairment).
* p < 0.005 vs. norm [median of the value observed in a US refer-
ence population of corresponding age and gender].
Table 2. Utility indices measured by different instruments in OSA 
patients
Standard gamble utility index (SG) (n = 65)
0.97 (0.89; 0.99)
Time trade-off utility index (TTO) (n = 56)
0.94 (0.81; 0.99)
EQ-5D utility index (n = 57)
0.92 (0.83; 1.00)*, **
Euro-thermometer visual analog scale 
utility index (VAS)
(n = 65)
0.80 (0.70; 0.90)*, **
SF-6D utility index (n = 66)
0.75 (0.69; 0.85)**
* p < 0.05, VAS utility vs. EQ-5D, and EQ-5D vs. TTO; ** p < 
0.001, SF-6D utility vs. TTO; SF-6D vs. SG; SF-6D vs. EQ-5D; 
VAS vs. TTO; VAS vs. SG, and EQ-5D vs. SG. 
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 Fig. 2. Distribution of the utility indices obtained by the various instruments and the AHI in 66 OSA patients. 
There is a ceiling effect in the standard gamble and time trade-off utility indices. 
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( table 3 ). Except for a weak correlation between the Ep-
worth sleepiness score and the standard gamble and time 
trade-off utility indices, none of the utility indices were 
correlated with measures of disease severity, e.g. the Ep-
worth sleepiness score or the AHI ( table 3 ).
 In 34 patients participating in our previous study  [17] , 
SF-36 data were re-analyzed to obtain SF-6D utility ( ta-
ble 4 ). The baseline SF-6D utility index was similar (me-
dian value of 0.74) to the corresponding value observed 
in the 66 patients in the current study (median value of 
0.75,  table 2 ). Computation of SF-6D utility indices after 
4 months of CPAP therapy in patients from the previous 
study revealed a significant improvement by a median of 
0.04 to 0.79 points ( table 4 ). Over the same time period, 
the AHI and the Epworth sleepiness score had also sig-
nificantly improved ( table 4 ).
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 Fig. 3. Correlations among utility indices 
obtained by various instruments and the 
AHI with the SF-6D utility index in 66 
OSA patients. The Spearman rank order 
correlation coefficient R is indicated. The 
dashed lines represent identity. 
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 Discussion 
 We evaluated subjective health perception by several 
direct and indirect utility instruments in OSA patients 
and found that utility indices derived from the five dif-
ferent instruments tested differed significantly and were 
only weakly correlated among themselves and with other 
generic measures of quality of life and with measures of 
disease severity, e.g. the Epworth sleepiness score and 
AHI. Utility indices obtained by the standard gamble and 
the time trade-off methods showed ceiling effects and 
seemed not to reflect the burden of disease in OSA pa-
tients. The Euro-thermometer visual analog scale and the 
SF-6D utility indices revealed the lowest values in OSA 
patients and the SF-6D utility index improved signifi-
cantly with CPAP therapy. Therefore, of the five instru-
ments tested, the SF-6D and the Euro-thermometer util-
ity indices seem to be the most suitable to reflect the im-
paired quality of life in OSA patients.
 Few previous studies have measured utility indices by 
various instruments in OSA patients. In a retrospective 
analysis of 19 OSA patients, Tousignant et al.  [22] report-
ed a mean standard gamble utility index of 0.63 before 
treatment and of 0.87 after several months of CPAP ther-
apy. In a randomized trial, Chakravorty et al.  [23] re-
corded a mean standard gamble utility index in 32 OSA 
patients of 0.32 before and of 0.55 during CPAP therapy. 
The utility indices of untreated OSA patients in the two 
cited studies  [22, 23] are lower than the corresponding 
values of 0.97 and 0.94 obtained with the standard gam-
ble and time trade-off methods in the current study ( ta-
ble 2 ). We have no definitive explanation for this discrep-
ancy since disease severity assessed by the AHI in our 
patients (median of 57/h,  table 1 ) was similar to that of 
Table 3. Correlations between utility indices, generic quality of life, Epworth sleepiness score and AHI in OSA patients 
Standard gamble 
utility index
Time trade-off 
utility index
EQ-5D 
utility index
Euro-thermometer
VAS utility index
SF-6D utility
index
Standard gamble utility index 0.50*** –0.09 0.15 0.12
Time trade-off utility index 0.50*** –0.01 0.21 0.07
EQ-5D utility index –0.09 –0.01 0.50*** 0.55***
Euro-thermometer VAS utility index 0.15 0.21 0.50*** 0.41***
SF-6D utility index 0.12 0.07 0.55*** 0.41***
SF-36 physical function –0.03 0.01 0.53*** 0.43*** 0.48***
SF-36 role physical 0.09 0.12 0.32* 0.37** 0.65***
SF-36 vitality 0.01 0.12 0.35** 0.30* 0.68***
EQ-5D pain/discomfort domain 0.14 0.02 –0.88*** –0.4** –0.49***
Epworth sleepiness score –0.28* –0.31* 0.05 0.00 –0.17
AHI –0.16 0.01 0.13 0.05 –0.00
Values are Spearman rank order correlations (R). * p < 0.05, ** p < 0.01, *** p < 0001; VAS = visual analog scale. Horizontal dashed 
lines separate direct from indirect utility indices and measures of disease severity, respectively.
Table 4. SF-6D utility indices in OSA patients before and 4 months after initiating CPAP therapy
Baseline 4 months on CPAP Change
Epworth score 15.0 (11.0; 17.0) 7.0 (4.0; 9.5) 7.0 (5.0; 9.0)**
AHI (events/h) 49.8 (34.8; 59.4) 5.0 (3.1; 8.6) 37.8 (26.2; 54.7)**
SF-6D utility index 0.74 (0.66; 0.81) 0.79 (0.68; 0.85) 0.04 (–0.02; 0.12)*
SF-6D utility was derived from data collected in a previous trial [17] in 33 OSA patients; values are medians (quartiles). * p = 0.026, 
** p < 0.000001.
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the patients in the studies cited (mean values of 67/h  [22] 
and 55/h  [23] before treatment), although socioeconom-
ic patient characteristics and aspects of the protocol and 
test application might have differed between the stud-
ies.
 In four studies  [23–26] comprising a total of 260 OSA 
patients, the mean EQ-5D utility indices before initiation 
of treatment were between 0.73 and 0.79, i.e. lower than 
the value of 0.92 observed in the current study ( table 2 ). 
In only one of these studies  [23] , initiation of CPAP ther-
apy was associated with a significant increase in the EQ-
5D utility index of 0.04 while CPAP had no significant 
effect on the index in the other three studies  [24–26] . 
Therefore, the authors concluded that the EQ-5D ques-
tionnaire might not capture the relevant quality-of-life 
domains affected in OSA patients  [24, 25] . Consistent 
with this interpretation, we found that EQ-5D quality of 
life was normal in OSA patients apart from a trend to a 
minor impairment in the pain/discomfort domain ( ta-
ble 1 ) and, accordingly, the EQ-5D utility indices were 
relatively high, suggesting a ceiling effect as previously 
observed in other patient groups  [27] ( table 2 ).
 In two of the studies cited  [23, 24] , the Euro-thermom-
eter visual analog scale has also been employed along 
with other utility instruments. In untreated OSA pa-
tients, the Euro-thermometer utility index was 0.67  [24] 
and 0.59  [23] , which increased by 0.04 and 0.11, respec-
tively, with CPAP therapy. In the current study, the Euro-
thermometer utility index was higher (median: 0.80,  ta-
ble 2 ) than the baseline value in the studies cited but low-
er than corresponding values derived in the same patients 
by the standard gamble, the time-trade-off and the EQ-
5D questionnaire ( table 2 ), suggesting that the Euro-ther-
mometer visual analog scale was able to better express the 
patients’ impaired quality of life. 
 Our study is the first to include SF-6D utility indices 
in quality-of-life assessment in OSA patients. The SF-6D 
indices were lower than those obtained by all other in-
struments ( table 2 ) and there was a significant improve-
ment in SF-6D utility of 0.04 with CPAP therapy ( table 4 ). 
This value falls well within the range of minimally im-
portant differences of 0.011–0.097 computed for SF-6D 
utility in patients with various diseases other than OSA 
(e.g. COPD and back pain)  [28] . Since SF-6D utility indi-
ces in the current study were correlated with quality of 
life assessed by the physical component summary of the 
SF-36 and with the pain/discomfort domain of the EQ-
5D as well as with the EQ-5D utility index and the Euro-
thermometer-derived utility index, the SF-6D index 
seems promising as a sensitive generic instrument for 
evaluation of utility and its changes with treatment in 
OSA patients.
 In line with divergent utility indices obtained by the 
EQ-5D and other instruments in previous studies in OSA 
 [22–26] and other diseases  [27, 28] , we found only a weak 
or no correlation among utility indices obtained by dif-
ferent instruments ( table 3 ). This was in part related to 
the ceiling effect observed in the standard gamble and 
time trade-off indices ( fig. 2 ). In our experience, the OSA 
patients in the current study did not perceive their disor-
der as directly life-threatening and were therefore reluc-
tant to accept even a minor risk of immediate death in the 
standard gamble, or to give up a portion of their lifetime 
in the time trade-off test. The weak or absent correlation 
between several utility indices and other measures of ge-
neric quality of life (i.e. SF-36 domains or the EQ-5D 
pain/discomfort domain) and with measures of OSA se-
verity such as the Epworth sleepiness scale or the AHI 
suggests that certain utility indices might not appropri-
ately reflect the burden of disease in OSA. Similarly, ge-
neric quality of life was poorly correlated with sleep-re-
lated breathing disturbances in OSA patients in previous 
studies  [29] . Further prospective trials are required to 
evaluate which utility instruments are most suitable to 
track treatment effects in OSA.
 In conclusion, we demonstrated that utility indices de-
rived by different instruments in OSA patients vary large-
ly and are poorly correlated among themselves. There-
fore, the interpretation of cost-effectiveness analysis 
based on utility assessment in OSA has to carefully ac-
count for the instruments used. Instruments established 
in other settings, such as the standard gamble and the 
time trade-off methods, provided relatively high utility 
indices (between 0.9 and 1.0) even in moderate/severe 
OSA. Apparently, these indices do not appropriately re-
flect the impaired quality-of-life domains of OSA pa-
tients and the improvement by treatment. Therefore, the 
SF-6D utility index and the Euro-thermometer visual an-
alog scale that revealed lower values that were correlated 
with other measures of generic quality of life seem better 
suited to reflect the disease state of OSA patients, and to 
track treatment-induced changes (by the SF-6D).
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